IP Library › Granted Patent US 12,630,628
Granted Patent B2
US 12,630,628 · App. 17/662,042 · Granted May 19, 2026

Anti-TIGIT antibodies and methods of use thereof

Inventors: Olga Ignatovich (Lexington, MA); K. Mark Bushell (Lexington, MA); Dhan Sidhartha Chand (Woburn, MA); Beth Wensley (Lexington, MA)
Assignee: Agenus Inc.
C07K16/2803A61K31/713A61K39/0011A61K39/001176A61K47/6817A61K47/6849C12N5/10C12N15/63A61K2039/507A61K45/06C07K2317/21C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,630,628
App. No.
17/662,042
Granted
May 19, 2026
Kind
B2
Abstract

The instant disclosure provides isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Claims (26)

1 . An isolated antibody that specifically binds to human TIGIT, the antibody comprising a VH comprising the amino acid sequence of SEQ ID NO: 7 or 8, and a VL comprising the amino acid sequence of SEQ ID NO: 9 or 10.

2 . The isolated antibody of claim 1 , wherein the antibody comprises the VH and VL amino acid sequences of SEQ ID NOs: 7 and 9.

3 . The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain constant region selected from the group consisting of human IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 , and IgA 2 .

4 . The isolated antibody of claim 3 , wherein the antibody comprises an IgG 1 heavy chain constant region, wherein:

(a) the IgG 1 heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 16;

(b) the amino acid sequence of the IgG 1 heavy chain constant region comprises an N297A mutation, numbered according to the EU numbering system;

(c) the amino acid sequence of the IgG 1 heavy chain constant region comprises S267E and L328F mutations, numbered according to the EU numbering system;

(d) the amino acid sequence of the IgG 1 heavy chain constant region comprises at least one mutation selected from the group consisting of S239D, A330L, and I332E mutations, numbered according to the EU numbering system; or

(e) the amino acid sequence of the IgG 1 heavy chain constant region comprises S239D, A330L, and I332E mutations, numbered according to the EU numbering system.

5 . The isolated antibody of claim 3 , wherein the antibody comprises a heavy chain constant region that is a variant of a wild type heavy chain constant region, wherein the variant heavy chain constant region binds to an FcγR with higher affinity than the wild type heavy chain constant region binds to the FcγR, wherein the FcγR is FcγRIIB or FcγRIIIA.

6 . The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 11, 12, 19, or 20, and/or a light chain comprising the amino acid sequence of SEQ ID NO: 13, 14, 15, or 21.

7 . The isolated antibody of claim 1 , wherein the antibody comprises a light chain constant region comprising the amino acid sequence of SEQ ID NO: 17 or 18.

8 . The isolated antibody of claim 1 , wherein:

(a) the antibody is multispecific;

(b) the antibody is conjugated to a cytotoxic agent, cytostatic agent, toxin, radionuclide, or detectable label; or

(c) the antibody is conjugated to an antibody.

9 . The isolated antibody of claim 1 , wherein the antibody comprises the VH and VL amino acid sequences of SEQ ID NOs: 7 and 10, respectively.

10 . A composition comprising the isolated antibody of claim 1 and a pharmaceutically acceptable carrier or excipient.

11 . The isolated antibody of claim 1 , wherein the antibody comprises the VH and VL amino acid sequences of SEQ ID NOs: 8 and 9.

12 . The isolated antibody of claim 1 , wherein the antibody comprises the VH and VL amino acid sequences of SEQ ID NOs: 8 and 10.

13 . The isolated antibody of claim 1 , wherein the antibody has a thermal melting temperature of about 77° to 80° C.

14 . An isolated antibody that specifically binds to human TIGIT, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 11, 12, 19, or 20, and a light chain comprising the amino acid sequence of SEQ ID NO: 13, 14, 15, or 21.

15 . The isolated antibody of claim 14 , wherein the heavy chain and light chain comprise the amino acid sequences of SEQ ID NOs: 11 and 13; 11 and 14; 11 and 15; 11 and 21; 12 and 13; 12 and 14; 12 and 15; 12 and 21; 19 and 13; 19 and 14; 19 and 15; 19 and 21; 20 and 13; 20 and 14; 20 and 15; or 20 and 21, respectively.

16 . The isolated antibody of claim 15 , wherein the heavy chain and light chain comprise the amino acid sequences of SEQ ID NOs: 11 and 13, or 19 and 13, respectively.

17 . A composition comprising the isolated antibody of claim 14 and a pharmaceutically acceptable carrier or excipient.

18 . The isolated antibody of claim 14 , wherein the antibody has a thermal melting temperature of about 77° to 80° C.

Assignments (2)
SECURITY INTEREST Recorded Mar 31, 2025
From: AGENUS, INC.
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 070680/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2023
From: IGNATOVICH, OLGA; BUSHELL, K. MARK; CHAND, DHAN SIDHARTHA; WENSLEY, BETH
To: AGENUS INC.
Reel/Frame 062675/0813 →
Continuity (2)
Provisional Application 63201536 · May 4, 2021
Related Publication 20220389095A1 · Dec 8, 2022
References Cited (136)
US 5585089A · Queen · 1996 [cited by examiner]
US 8211431B2 · Throsby · 2012 [cited by examiner]
US 9499596B2 · Clark et al. · 2016 [cited by applicant]
US 9695238B2 · Gao et al. · 2017 [cited by applicant]
US 9713641B2 · Hicklin et al. · 2017 [cited by applicant]
US 9725515B2 · Anderson · 2017 [cited by examiner]
US RE46534E · Baldwin et al. · 2017 [cited by applicant]
US 9873740B2 · Grogan et al. · 2018 [cited by applicant]
US 10017572B2 · Grogan et al. · 2018 [cited by applicant]
US 10112997B2 · Gurney et al. · 2018 [cited by applicant]
US 10124061B2 · White et al. · 2018 [cited by applicant]
US 10144778B2 · Eisenbach-Schwartz et al. · 2018 [cited by applicant]
US 10189902B2 · Maurer et al. · 2019 [cited by applicant]
US 10329349B2 · Cooper et al. · 2019 [cited by applicant]
US 10501737B2 · Ishii · 2019 [cited by applicant]
US 10537633B2 · Tso et al. · 2020 [cited by applicant]
US 10537637B2 · Sheng et al. · 2020 [cited by applicant]
US 11021537B2 · Chand et al. · 2021 [cited by applicant]
US 11680098B2 · Chand et al. · 2023 [cited by applicant]
US 20090258013A1 · Clark et al. · 2009 [cited by applicant]
US 20130287777A1 · Duffy et al. · 2013 [cited by applicant]
US 20130287797A1 · Heider et al. · 2013 [cited by applicant]
US 20160108123A1 · Freeman et al. · 2016 [cited by applicant]
US 20160152720A1 · Kim et al. · 2016 [cited by applicant]
US 20160193239A1 · Baylin et al. · 2016 [cited by applicant]
US 20160376371A1 · Ravetch et al. · 2016 [cited by applicant]
US 20170037127A1 · Grogan et al. · 2017 [cited by applicant]
US 20170107300A1 · Kuchroo et al. · 2017 [cited by applicant]
US 20170143825A1 · Grogan · 2017 [cited by applicant]
US 20170239338A1 · Szalay et al. · 2017 [cited by applicant]
US 20170260271A1 · Igawa et al. · 2017 [cited by applicant]
US 20170360932A1 · Parry · 2017 [cited by applicant]
US 20180066055A1 · Williams et al. · 2018 [cited by applicant]
US 20180078625A1 · Moon et al. · 2018 [cited by applicant]
US 20180155422A1 · Bhatt et al. · 2018 [cited by applicant]
US 20180169239A1 · Grogan · 2018 [cited by applicant]
US 20180185480A1 · Mandelboim et al. · 2018 [cited by applicant]
US 20180251548A1 · Sabzevari et al. · 2018 [cited by applicant]
US 20180355040A1 · Chand et al. · 2018 [cited by applicant]
US 20180371083A1 · Williams et al. · 2018 [cited by applicant]
US 20190077869A1 · Fiedler et al. · 2019 [cited by applicant]
US 20200040082A1 · Piasecki et al. · 2020 [cited by applicant]
US 20200062859A1 · Piasecki et al. · 2020 [cited by applicant]
US 20200255516A1 · Fu et al. · 2020 [cited by applicant]
US 20200331999A1 · Zhang et al. · 2020 [cited by applicant]
US 20210101977A1 · Chand et al. · 2021 [cited by applicant]
US 20220089732A1 · Chand et al. · 2022 [cited by applicant]
US 20230014036A1 · Chand et al. · 2023 [cited by applicant]
US 20240141039A1 · Chand et al. · 2024 [cited by applicant]
US 20240141047A1 · Chand et al. · 2024 [cited by applicant]
US 20240209082A1 · Chand et al. · 2024 [cited by applicant]
EP 3712170A1 · 2020 [cited by applicant]
WO WO2011109789A2 · 2011 [cited by applicant]
WO 2013165894A2 · 2013 [cited by applicant]
WO WO2013184912A2 · 2013 [cited by applicant]
WO 2015024060A1 · 2015 [cited by applicant]
WO WO2016004875A1 · 2016 [cited by applicant]
WO WO2016011264A1 · 2016 [cited by applicant]
WO WO2016180781A1 · 2016 [cited by applicant]
WO WO2016191643A2 · 2016 [cited by applicant]
WO WO2017023749A1 · 2017 [cited by applicant]
WO WO2017030823A2 · 2017 [cited by applicant]
WO 2017053748A2 · 2017 [cited by applicant]
WO WO2017040790A1 · 2017 [cited by applicant]
WO WO2017048824A1 · 2017 [cited by applicant]
WO WO2017059095A1 · 2017 [cited by applicant]
WO WO2017062619A2 · 2017 [cited by applicant]
WO WO2017062820A1 · 2017 [cited by applicant]
WO WO2017123981A1 · 2017 [cited by applicant]
WO WO2017223085A2 · 2017 [cited by applicant]
WO WO2018053242A1 · 2018 [cited by applicant]
WO WO2018102536A1 · 2018 [cited by applicant]
WO WO2018183889A1 · 2018 [cited by applicant]
WO WO2018204363A1 · 2018 [cited by applicant]
WO WO2018204405A1 · 2018 [cited by applicant]
WO WO2018229163A1 · 2018 [cited by applicant]
WO WO2018234793A2 · 2018 [cited by applicant]
WO WO2019062832A1 · 2019 [cited by applicant]
WO 2019091449A1 · 2019 [cited by applicant]
WO WO2019129221A1 · 2019 [cited by applicant]
WO WO2019129261A1 · 2019 [cited by applicant]
WO WO2019137548A1 · 2019 [cited by applicant]
WO WO2019152574A1 · 2019 [cited by applicant]
WO WO2019154415A1 · 2019 [cited by applicant]
WO WO2019165434A1 · 2019 [cited by applicant]
WO WO2019168382A1 · 2019 [cited by applicant]
WO 2020092554A1 · 2020 [cited by applicant]
WO 2020132034A1 · 2020 [cited by applicant]
WO 2020185739A1 · 2020 [cited by applicant]
WO 2020242919A1 · 2020 [cited by applicant]
WO 2020263879A1 · 2020 [cited by applicant]
WO 2021042019A1 · 2021 [cited by applicant]
Almagro et. al., Front. Immunol. 2018; 8:1751 (Year: 2018). [cited by examiner]
Chiu ML et al. Antibodies 2019 8, 55, 1-80 (Year: 2019). [cited by examiner]
Haidar, J.N, et. al. A universal combinatorial design of antibody framework to graft distinct CDR sequences: a bioinformatics approach. Proteins: Structure, function, and bioinformatics, 80(3), pp. 896-912 (Year: 2011). [cited by examiner]
PCT International Search Report from PCT/US2022/072110 dated Sep. 12, 2022. [cited by applicant]
U.S. Appl. No. 15/968,094 2018-03555040 U.S. Pat. No. 11,021,537, filed May 1, 2018 Dec. 13, 2018 Jun. 1, 2021, Dhan Sihartha Chand. [cited by applicant]
U.S. Appl. No. 17/240,944 2022-0089732, filed Apr. 26, 2021 Mar. 24, 2022, Dhan Sidhartha Chand. [cited by applicant]
Agenus, “Corporate Presentation,” Cantor Fitzgerald Global Healthcare Conference. Sep. 2017. [cited by applicant]
Agenus, “Integrated Immunotherapy: Enabling Best-in-Class I-O Combinations,” Non-Confidential Overview. Nov. 2017. [cited by applicant]
Blake et al., “Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy,” Clin Cancer Res. Nov. 1, 2016;22(21):5183-5188. [cited by applicant]
Cattaruzza et al., “Pharmacodynamic biomarkers for anti-TIGIT treatment and prevalence of TIGIT expression in multiple solid tumor types,” OncoMed Pharmaceuticals. 2017. [cited by applicant]
Chauvin et al., “TIGIT and PD-1 impair tumor antigen-specific CD8? T cells in melanoma patients,” J Clin Invest. May 2015;125(5):2046-58. [cited by applicant]
Chew et al., “TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection,” PLOS Pathog. Jan. 7, 2016;12(1):e1005349. [cited by applicant]
Dougall et al., “TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy,” Immunol Rev. Mar. 2017;276(1):112-120. [cited by applicant]
Gur et al., “Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack,” Immunity. Feb. 17, 2015;42(2):344-355. [cited by applicant]
He et al., “CD155T/TIGIT Signaling Regulates CD8 + T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer,” Cancer Res. Nov. 15, 2017;77(22):6375-6388. [cited by applicant]
Hung et al., “TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM,” Oncoimmunology. May 24, 2018;7(8):e1466769. [cited by applicant]
Johnston et al., “The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function,” Cancer Cell. Dec. 8, 2014;26(6):923-937. [cited by applicant]
Joller et al., “Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses,” Immunity. Apr. 17, 2014;40(4):569-81. [cited by applicant]
Kurtulus et al., “TIGIT predominantly regulates the immune response via regulatory T cells,” J Clin Invest. Nov. 2, 2015;125(11):4053-62. [cited by applicant]
Lozano et al., “The TIGIT/CD226 axis regulates human T cell function,” J Immunol. Apr. 15, 2012;188(8):3869-75. [cited by applicant]
Manieri et al., “TIGIT: A Key Inhibitor of the Cancer Immunity Cycle,” Trends Immunol. Jan. 2017;38(1):20-28. [cited by applicant]
Meibohm et al., “The role of pharmacokinetics and pharmacodynamics in the development of biotech drugs,” Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. Weinheim,… [cited by applicant]
Pauken and Wherry, “TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit,” Cancer Cell. Dec. 8, 2014;26(6):785-787. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2018/030453, dated Jul. 17, 2018. [cited by applicant]
Samanta et al., “Structural, mutational and biophysical studies reveal a canonical mode of molecular recognition between immune receptor TIGIT and nectin-2,” Mol Immunol. Jan. 2017;81:151-159. [cited by applicant]
Stanietsky et al., “The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity,” Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63. [cited by applicant]
Stein, “Next generation immunomodulatory antibodies: optimizing therapeutic impact,” 2017. [cited by applicant]
Stengel et al., “Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering,” Proc Natl Acad Sci USA. Apr. 3, 2012;109… [cited by applicant]
White et al., “Antibody-targeted immunotherapy for treatment of malignancy,” Annu Rev Med. 2001; 52: 125-45. [cited by applicant]
Yu et al., “The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells,” Nat Immunol. Jan. 2009;10(1):48-57. [cited by applicant]
Zhou et al., “Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8 + T Cells,” Front Immunol. Nov. 29, 2018;9:2821. [cited by applicant]
Lazar et al., “Engineered antibody Fc variants with enhanced effector function” Proc. Natl. Acad. Sci. USA., 2016. 103(11); pp. 4005-4010. [cited by applicant]
Ha et al., Immunoglobulin Fc Heterodimer Platform Technology: From Design to Application in Therapeutic Antibodies and Proteins Fron. Immunol. 2016. 7(349); 16 pages. [cited by applicant]
Aguilera et al., “CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity”, Oncoimmunology, 2018, 7(5):e1424677, pp. e1424677-1-e1424677-10. [cited by applicant]
Gorvel et al., “Targeting the “PVR-TIGIT axis” with immune checkpoint therapies”, F1000Research, 2020, 9(F1000 Faculty Rev):354, pp. 1-10. [cited by applicant]
Oganesyan et al., “Structural characterization of a mutated, ADCC-enhanced human Fc fragment”, Molecular Immunology, 2008, 45(7):1872-1882. [cited by applicant]
Spasevska et al., “Advances in Bispecific Antibodies Engineering: Novel Concepts for Immunotherapies”, Journal of Blood Disorders and Transfusion, 2015, 6(1):1000243, pp. 1-8. [cited by applicant]
Ward et al., “Abstract 253: Anti-TIGIT Antibodies Require Enhanced FcGammaR Co-Engagement for Optimal T and NK Cell-Dependent Anti-Tumor Immunity”, Journal of Immunotherapy and Cancer, 2020, 8(Suppl 3):A153. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/US2018/030453, completed on Jul. 31, 2019, 14 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/US2022/072099, mailed on Nov. 16, 2023, 15 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/US2022/072110, mailed on Nov. 16, 2023, 8 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/US2020/048700, mailed on Dec. 8, 2020, 20 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/US2022/072099, mailed on Oct. 6, 2022, 23 pages. [cited by applicant]
Mittal et al., “CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function Free”, Cancer Immunology Research, Apr. 2019, 7(4):559-571. [cited by applicant]